Hjem
Karl-Henning Kallands bilde

Karl-Henning Kalland

Professor
  • E-postKalland@uib.no
  • Telefon+47 55 58 45 06
  • Besøksadresse
    Haukeland universitetssykehus, Laboratoriebygget
  • Postadresse
    Postboks 7804
    5020 Bergen
Vitenskapelig artikkel
  • 2019. PIK3CA amplification associates with aggressive phenotype but not markers of AKT-mTOR signaling in endometrial carcinoma. Clinical Cancer Research. 334-345.
  • 2018. Small molecule promotes β-catenin citrullination and inhibits Wnt signaling in cancer. Nature Chemical Biology. 94-101.
  • 2018. Screening for viral nucleic acids in vestibular schwannoma. Journal of Neurovirology. 730-737.
  • 2018. Identification of highly connected and differentially expressed gene subnetworks in metastasizing endometrial cancer. PLOS ONE. 1-21.
  • 2018. Dual androgen receptor (AR) and STAT3 inhibition by a compound targeting the AR amino-terminal domain. Pharmacology Research & Perspectives. 1-15.
  • 2017. Tumour-associated glial host cells display a stem-like phenotype with a distinct gene expression profile and promote growth of GBM xenografts. BMC Cancer. 1-13.
  • 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • 2017. PIK3CA exon9 mutations associate with reduced survival, and are highly concordant between matching primary tumors and metastases in endometrial cancer. Scientific Reports. 1-12.
  • 2017. HER2 expression patterns in paired primary and metastatic endometrial cancer lesions. British Journal of Cancer. 378-387.
  • 2017. An androgen response element driven reporter assay for the detection of androgen receptor activity in prostate cells. PLOS ONE. 1-20.
  • 2016. Expression of circadian clock genes and proteins in urothelial cancer is related to cancer-associated genes. BMC Cancer. 17 sider.
  • 2016. Context dependent regulatory patterns of the androgen receptor and androgen receptor target genes. BMC Cancer. 15 sider.
  • 2016. Axitinib blocks Wnt/β-catenin signaling and directs asymmetric cell division in cancer. Proceedings of the National Academy of Sciences of the United States of America. 9339-9344.
  • 2016. Aneuploidy related transcriptional changes in endometrial cancer link low expression of chromosome 15q genes to poor survival. OncoTarget. 9696-9707.
  • 2016. Androgen receptor as potential therapeutic target in metastatic endometrial cancer. OncoTarget. 49289-49298.
  • 2015. Tumor necrosis is an important hallmark of aggressive endometrial cancer and associates with hypoxia, angiogenesis and inflammation responses. OncoTarget. 39676-39691.
  • 2015. Molecular profiling of endometrial carcinoma precursor, primary and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. OncoTarget. 1327-1339.
  • 2015. Increased angiogenesis is associated with a 32-gene expression signature and 6p21 amplification in aggressive endometrial cancer. OncoTarget. 10634-10645.
  • 2015. ATAD2 overexpression links to enrichment of B-MYBtranslational signatures and development of aggressive endometrial carcinoma. OncoTarget. 28440-28452.
  • 2014. Switch in FOXA1 status associates with endometrial cancer progression. PLOS ONE.
  • 2014. Spontaneous reversion of the angiogenic phenotype to a nonangiogenic and dormant state in human tumors. Molecular Cancer Research. 754-764.
  • 2014. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. OncoTarget. 1052-1061.
  • 2014. High level of HSF1 associates with aggressive endometrial carcinoma and suggests potential for HSP90 inhibitors. British Journal of Cancer. 78-84.
  • 2014. Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. Gynecologic Oncology. 599-606.
  • 2013. p63 attenuates epithelial to mesenchymal potential in an experimental prostate cell model. PLOS ONE. 12 sider.
  • 2013. MiR-182 and miR-203 induce mesenchymal to epithelial transition and self-sufficiency of growth signals via repressing SNAI2 in prostate cells. International Journal of Cancer. 544-555.
  • 2013. Lack of estrogen receptor-alpha is associated with epithelial-mesenchymal transition and PI3K alterations in endometrial carcinoma. Clinical Cancer Research. 1094-1105.
  • 2013. Integrated genomic analysis of the 8q24 amplification in endometrial cancers identifies ATAD2 as essential to MYC-dependent cancers. PLOS ONE. 9 sider.
  • 2013. High phospho-stathmin(Serine38) expression identifies aggressive endometrial cancer and suggests an association with PI3K inhibition. Clinical Cancer Research. 2331-2341.
  • 2013. Generation of prostate tumor-initiating cells is associated with elevation of reactive oxygen species and IL-6/STAT3 signaling. Cancer Research. 7090-7100.
  • 2013. Gene set based integrated data analysis reveals phenotypic differences in a brain cancer model. PLOS ONE. 11 sider.
  • 2013. Differences in proliferative capacity of primary human acute myelogenous leukaemia cells are associated with altered gene expression profiles and can be used for subclassification of patients. Cell Proliferation. 554-562.
  • 2013. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Modern Pathology. 428-434.
  • 2012. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proceedings of the National Academy of Sciences of the United States of America. 8699-8704.
  • 2012. Loss of GPER identifies new targets for therapy among a subgroup of ER alpha-positive endometrial cancer patients with poor outcome. British Journal of Cancer. 1682-1688.
  • 2012. Lipocalin 2 expression is associated with aggressive features of endometrial cancer. BMC Cancer. 7 sider.
  • 2012. KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer. British Journal of Cancer. 1997-2004.
  • 2012. High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated. PLOS ONE.
  • 2012. Gene expression in tumor cells and stroma in dsRed 4T1 tumors in eGFP-expressing mice with and without enhanced oxygenation. BMC Cancer. 10 sider.
  • 2011. Transcribed DNA is preferentially located in the perichromatin region of mammalian cell nuclei. Experimental Cell Research. 433-444.
  • 2011. Reprogramming of cell junction modules during stepwise epithelial to mesenchymal transition and accumulation of malignant features in vitro in a prostate cell model. Experimental Cell Research. 234-247.
  • 2011. High BMI is significantly associated with positive progesterone receptor status and clinico-pathological markers for non-aggressive disease in endometrial cancer. British Journal of Cancer. 921-926.
  • 2011. Gene Expression Patterns Related to Vascular Invasion and Aggressive Features in Endometrial Cancer. American Journal of Pathology. 861-871.
  • 2011. Amplification of the 20q chromosomal arm occurs early in tumorigenic transformation and may initiate cancer. PLOS ONE. 15 sider.
  • 2010. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors: release profile and pharmacological modulation. European Journal of Haematology. 239-251.
  • 2010. Global profiling of histone and DNA methylation reveals epigenetic-based regulation of gene expression during epithelial to mesenchymal transition in prostate cells. BMC Genomics. 15 sider.
  • 2009. TMPRSS2:ERG fusion transcripts in urine from prostate cancer patients correlate with a less favorable prognosis. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 575-582.
  • 2009. Primary human acute myeloid leukaemia cells increase the proliferation of microvascular endothelial cells through the release of soluble mediators. British Journal of Haematology. 53-68.
  • 2009. Primary human acute myelogenous leukemia cells release matrix metalloproteases and their inhibitors; release profile and pharmacological modulaion. European Journal of Haematology. 239-251.
  • 2009. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. British Journal of Haematology. 53-68.
  • 2009. Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation. Proceedings of the National Academy of Sciences of the United States of America. 4834-4839.
  • 2009. Hyperoxic treatment induces mesenchymal to epithelial transition in a rat adenocarcinoma model. PLOS ONE.
  • 2009. Highly infiltrative brain tumours show reduced chemosensitivity associated with a stem cell-like phenotype. Neuropathology and Applied Neurobiology. 380-393.
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLOS ONE. 14 sider.
  • 2009. Genes of cell-cell interactions, chemotherapy detoxification and apoptosis are induced during chemotherapy of acute myeloid leukemia. BMC Cancer.
  • 2009. Cytokines are produced locally by myocytes in rat skeletal muscle during endotoxemia. American Journal of Physiology. Heart and Circulatory Physiology. H735-H744.
  • 2008. WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clinical Cancer Research. 1397-1406.
  • 2008. Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia. 287-293.
  • 2008. Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. British Journal of Cancer. 1662-1669.
  • 2008. Epithelial to Mesenchymal Transition of a Primary Prostate Cell Line with Switches of Cell Adhesion Modules but without Malignant Transformation. PLOS ONE.
  • 2007. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 332-341.
  • 2007. Increased expression of sim2-s protein is a novel marker of aggressive prostate cancer. Clinical Cancer Research. 892-897.
  • 2007. Hyperoxia retards growth and induces apoptosis, changes in vascular density and gene expression in transplanted gliomas in nude rats. Journal of Neuro-Oncology. 191-202.
  • 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukamia cells indentify patient subgroups that differ susceptibility to histone deactylase inhibitors. International Journal of Oncology. 1529-1538.
  • 2007. ERG upregulation and related ETS transcription factors in prostate cancer. International Journal of Oncology. 19-32.
  • 2007. Comparison of nucleic acid targets prepared from total RNA or poly(A) RNA for DNA oligonucleotide microarray hybridization. Analytical Biochemistry. 46-58.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. International Journal of Oncology. 1065-1080.
  • 2006. Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2 : Bax ratio and low levels of heat shock protein 70 and 90. Leukemia Research. 1531-1540.
  • 2006. Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 16466-16471.
  • 2006. A distinct p53 protein isoform signature reflects the onset of induction chemotherapy for acute myeloid leukemia. Clinical Cancer Research. 3985-3992.
  • 2005. Nucleic-acid based diagnostics in clinical microbiology. Tidsskrift for Den norske legeforening. 3110-3114.
  • 2005. Gene expression profiles in prostate cancer: Association with patient subgroups and tumour differentiation. International Journal of Oncology. 329-336.
  • 2005. CD34 expression in native human acute myelogenous leukemia blasts: Differences in CD34 membrane molecule expression are associated with different gene expression profiles. Cytometry. 18-27.
  • 2003. Cellular localisation and nuclear export of the human bZIP transcription factor TCF11. Biochimica et Biophysica Acta. 143-151.
  • 2002. Rev inhibition strongly affects intracellular distribution of HIV-1 RNAs. Journal of Virology. 10473-10484.
  • 2002. Nuclear import of factors involved in signaling is inhibited in C3H/10T1/2 cells treated with tetradecylthioacetic acid. Journal of Lipid Research. 1630-1640.
  • 2002. Analysis of acute myelogenous leukemia: preparation of samples for genomic and proteomic analyses. Journal of Hematotherapy & Stem Cell Research. 469-481.
  • 2001. Mitochondrial protein p32 can accumulate in the nucleus. Biochemical and Biophysical Research Communications - BBRC. 1161-1169.
  • 2000. Identification of a nuclear ribonucleoprotein particle which contains incompletely spliced HIV-1 RNAs. Biochemical and Biophysical Research Communications - BBRC. 509-513.
  • 1999. Nukleinsyrebasert mikrobiolgoisk diagnostikk. Tidsskrift for Den norske legeforening. 802-809.
  • 1999. Co-expression of a trans-dominant negative mutant of the human immunodeficiency virus type 1 (HIV-1) Rev protein affects the Rev-dependent splicing pattern and expression of HIV-1 RNAs. Journal of General Virology. 1965-1974.
  • 1999. A trans-dominant negative mutant of the HIV-1 Rev protein affects the Rev-dependent splicing pattern and expression of HIV RNA. Journal of General Virology. 1965-1974.
  • 1998. Visualisation of ribosomal RNA (rRNA) synthesis in eukaryotic cells in culture. Methods in Cell Science. 295-302.
  • 1998. Subcellular localization of human immunodeficiency virus type 1 RNAs, Rev, and the splicing factor SC-35. Virology. 473-482.
  • 1998. Labelling of eukaryotic RNA transcripts with BrUTP using liposomal (DOTAP) and non-liposomal (FuGENE 6) transfection reagents: new application for transfection reagents. Biochemica. 45-46.
  • 1998. Histographic recording of human immunodeficiency virus type 1 (HIV-1) regulatory protein Rev and nuclear factors. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 623-635.
  • 1997. Oligomerization of HIV-1 Rev mutants in the cytoplasm and during nuclear import. Virology. 73-81.
  • 1997. Labelling of RNA transcripts of eukaryotic cells in culture with Br UTP using a liposome transfection reagent (DOTAP). BioTechniques. 308-312.
  • 1996. Immunoglobin G sublass antibodies to rubella viruses in chronic liver disease, acute rubella and healthy controls. FEMS Immunology and Medical Microbiology. 43-50.
  • 1996. HIV-1 proviral DNA sequences of env PCR amplificates from Tanzania. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 459-464.
  • 1995. Raised levels of antibodies to human viruses at the clinical onset of autoimmune chronic active hepatitis. Journal of Viral Hepatitis. 159-164.
  • 1995. Nuclear export of the human immunodeficiency virus type 1 nucleocytoplasmic shuttle protein Rev is mediated by its activation domain and is blocked by transdominant negative mutants. Journal of Virology. 3315-3323.
  • 1994. Viral antibodies in infectious mononucleosis. FEMS Immunology and Medical Microbiology. 219-224.
  • 1994. Radioimmunoprecipitation and immunoblot studies of antibodies to rubella virus in patients with chronic liver disease. Archives of Virology. 73-85.
  • 1994. Elevated rubella antibodies in patients with chronic liver diseases. Journal of Medical Virology. 30-36.
  • 1993. Diagnosis of infection with human T-cell lymphotropic virus type 2 (HTL V-2) in Norwegian HIV infected individuals. Clinical and Diagnostic Virology. 143-152.
  • 1991. Viral RNA species in cell lines persistently and lytically infected with measles virus. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 42-48.
  • 1991. Study of transcription in measles virus infected Vero cells using cDNA probes prepared from poly(A)RNA from uninfected and infected cells. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 33-41.
  • 1991. Rex-dependent nucleolar accumulation of HTLV-1 mRNA. The New Biologist. 389-397.
  • 1991. Replication of HIV-1 in primary dendritic cell cultures. Proceedings of the National Academy of Sciences of the United States of America. 7998-8002.
  • 1991. Presence of cfaD-homologous sequences and expression of coli surface antigen 4 on enterotoxigenic Escherichia coli; relevance for diagnostic procedures. Microbial Pathogenesis. 297-304.
  • 1990. Applications of Magnetic Beads With Covalently Attached Oligonucleotides in Hybridization: Isolation and Detection of Specific Measles Virus mRNA from Crude Cell Lysate. Analytical Biochemistry. 40-50.
  • 1989. Mechanism of spontaneous loss of heat-stable toxin (STa) Production in enterotoxigenic Escherichia coli. Acta Pathologica, Microbiologica et Immunologica Scandinavica (APMIS). 436-440.
  • 1988. Comparative Study of Colony Hybridization With Synthetic Oligonucleotide Probes and Enzyme-Linked Immunosorbent Assay for Identification of Enterotoxigenic Escherichia Coli. Journal of Clinical Microbiology. 530-534.
Populærvitenskapelig foredrag
  • 2007. Virus og kreft.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer.
Vitenskapelig foredrag
  • 2009. Genome-wide profiling of histone H3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis.
  • 2009. EMT Promotes Malignant Transformation of Prostate Epithelial Cells in Culture.
  • 2009. A novel cell culture model of prostate carcinogenesis and its utility in phenotypic screening of small molecular compounds.
  • 2008. Targeting master regulatory mechanisms in cancer therapy using novel small molecular compounds – basic mechanisms, in vitro and in vivo screening and development towards the clinic.
  • 2008. Regulatory patterns of prostate carcinogenesis and development of a cell culture experimental system.
  • 2008. Polycomb group target genes and bivalent H3K4 & K27me3 modifications in human embryonic cells were enriched among dysregulated genes in prostate cancer.
  • 2008. Epithelial to mesenchymal transition of a primary, immortalized prostate cell line is associated with gene expression switches of entire cell attachment modules.
  • 2007. Functional oncogenomics and epigenomics analysis of prostate cancer.
  • 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients and identification of ERG target genes.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer.
  • 2006. ERG upregulation and related transcription factors in prostate cancer.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer.
  • 2005. Onkogene, hepatotrope virus – molekylære mekanismer ved utvikling av hepatocellulært carcinom (HCC).
  • 2005. Nuclear localization of active genes and their transcripts.
  • 2005. Discovering candidate genes that distinguish between CML and AML using microarrays.
  • 2004. Virus and cancer models.
  • 2004. Real time quantitative PCR and hepatitis C monitoring.
  • 2004. Global analysis of gene expression and regulatory modules in cancer tissue.
  • 2004. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • 2004. Gene expression profiles in prostate cancer: identification of upregulated SIM2 gene validated in archival tissue, relation to histological grading and prognosis.
  • 2003. Virus og Cancer.
  • 2003. Global analysis of gene expression and regulatory patterns in urogenital tumours using DNA microarrays.
  • 2003. Global analysis of gene expression and regulatory patterns in cancer.
  • 2003. Global analysis of gene expression and regulatory patterns in acute myeloid leukemia.
  • 2003. Gene expression profiling in prostate cancer: cluster analysis and association with tumor differentation.
  • 2003. Gene expression profiling in prostate cancer.
  • 2003. Comparison of DNA microarray and real time quantitative PCR for quantitation of gene expression of selected genes in prostate cancer.
  • 2001. Global gene expression profiling using DNA microarrays - pitfalls and outlook.
  • 2001. Global analysis of gene expression in human cancer.
  • 2001. Angiostatin release from alginate encapsulated 293-cells.
Anmeldelse
  • 2007. Immunologiske refleksjonar - "Defending Life" av Elling Ulvestad, London - Springer forlag ISBN 978-1-4020-5675-8. Tidsskrift for Den norske legeforening. 3298-3299.
Fagbok
  • 1991. Kompendium i virologi. [Mangler utgivernavn].
  • 1989. Southeast Asia between Autocracy and Democracy. Aarhus Universitetsforlag.
Populærvitenskapelig artikkel
  • 1998. HIV som modellsystem til forståing av genekspresjon. Naturen. 67-77.
Kronikk
  • 1993. HTLV-I-infeksjon i Norge. Natl Inst Publ Health Rep (MSIS).
Doktorgradsavhandling
  • 2018. Regulatory patterns in prostate cell differentiation – investigation of transcription factors AR, GATA2 and NKX3-1.
  • 2017. Context dependent transcription factor regulation in normal and malignant cell differentiation.
  • 1989. Studies on measles virus in lytic and persistent infections ; Construction and use of measles virus specific nucleic acid probes.
Intervju
  • 2013. Til hjelp for andre i 40 år - Tordis og Fritz C. Riebers legat 1973 - 2013.
  • 2013. Skreddersyr medisiner mot kreft.
  • 2013. Omprogrammerer celler - utforsker nye angrepsmål ved prostatakreft.
  • 2013. Legat-jubileum: midler til kreftforskning.
  • 2008. Verdens Gang - Professorat betalt av GlaxoSmithKline ved Universitetet i Bergen.
  • 2008. Bergens Tidende - Vil ha DNA-lab i Bergen.
  • 2007. Livmorhalskreft.
  • 2005. Legionella og andre bakterier.
  • 2005. Gades Institutt - presentasjon.
  • 2005. Gades Institutt - presentasjon.
  • 2003. Bakterier og virus - slik beskytter du deg.
  • 2001. Bakterier og virus.
Vitenskapelig Kapittel/Artikkel/Konferanseartikkel
  • 2017. Models of Tumor Progression in Prostate Cancer. 16 sider.
  • 2009. Molecular Microbiological Diagnostics.
  • 1998. Mikrobiologisk diagnostikk. Kapittel om Nukleinsyrebasert diagnostikk.
  • 1991. Retroviral regulatory proteins and the nucleolus. 14 sider.
  • 1991. HIV-1 infection of human dendritic cells. 15 sider.
Sammendrag/abstract
  • 2013. FOXA1 LOSS IN ENDOMETRIAL CANCER IS ASSOCIATED WITH POOR PROGNOSIS AND ER ALPHA LOSS. International Journal of Gynecological Cancer. 1 sider.
  • 2012. Estrogen receptor a loss in endometrial carcinoma is associated with epithelial-to-mesenchymal transition and a potential for PI3Kinase inhibition. Virchows Archiv. S18-S18.
  • 2011. TUMOR-ASSOCIATED GLIAL CELLS PROMOTE GROWTH OF GBM XENOGRAFTS IN EGFP NOD/SCID MICE. Neuro-Oncology. 55-55.
  • 2009. PRIMARY HUMAN ACUTE MYELOGENOUS LEUKEMIA CELLS SHOW CONSTITUTIVE RELEASE OF SEVERAL MATRIX METALLOPROTEASES AND THEIR INHIBITORS. Haematologica. 545-545.
  • 2007. Release of angiopoietin-1 by acute myelogenous leukemia (AML) cells is increased by stromal cells and associated with mutations in the nucleophosmin (NPM) gene. Experimental Hematology. 72-72.
  • 2007. Linking susceptibility to histone deactylase inhibitors and basal gene expression profiles in acute myeloid leukaemia. Experimental Hematology. 77-77.
  • 2007. Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in the susceptibility to histone deacetylase inhibitors. Haematologica. 112-112.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation. NBS-nytt. 106.
  • 2006. The early gene expression signature of acute myeloid leukemia (AML) blasts during in vivo chemotherapy. International Journal of Molecular Medicine. S65.
  • 2006. Global gene expression analysis of transcription factors in prostate cancer and cell lines. International Journal of Molecular Medicine. S27.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer. NBS-nytt. 72.
  • 2005. Single-minded 2 homolog gene is overexpressed in prostate cancer. Virchows Archiv. 432-432.
  • 2005. Overexpression of ERG and SIM2 transcription factors in prostate cancer. International Journal of Molecular Medicine. S76-S76.
Poster
  • 2009. A novel model of stepwise prostate carcinogenesis in culture.
  • 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • 2007. Patterns of gene expression related to vascular invasion and aggressive features in endometrial cancer.
  • 2007. Early gene expression signature of chemotherapy treated acute myeloid leukemia in vivo.
  • 2007. Detection of TMPRSS2:ERG translocations in the urine of prostate cancer patients.
  • 2006. cDNA microarray analysis of non-selected cases of acute myeloid leukemia demonstrates distinct clustering independent of cytogenetic aberrations and consistent with morphological signs of differentiation.
  • 2006. Single-minded 2 homolog (SIM2) is overexpressed in prostate cancer.
  • 2006. Identification of deletions in clinical Mycobacterium tuberculosis isolates using comparative genomic hybridisation.
  • 2006. Gene expression profiles identify an aggressive phenotype in endometrial carcinoma.
  • 2006. ERG upregulation in relation to other transcription factors in prostate cancer.
  • 2006. Dynamics of global macrophage expression responses to in vitro infection with wild-type and a hypervirulent mce1-mutant of M. tuberculosis.
  • 2005. Very high expression of specific transcription factors in prostate cancer compared with paired benign prostate tissue.
  • 2005. Single-minded 2 homolog gene (SIM2) is overexpressed in prostate cancer.
  • 2005. ETS transcription factors in prostate cancer.
  • 2005. Analysis of treatment response in acute myeloid leukemia patients using DNA microarrays.
  • 2003. Gene expression profiling in prostate cancer refined by pairwise comparisons of cDNA microarrays from benign and malignant tissue.
  • 2001. Rev inhibition and nucleocytoplasmic transport of HIV RNAs.
Vitenskapelig oversiktsartikkel/review
  • 2018. Targeting Wnt/β-catenin signaling for cancer immunotherapy. 648-658.
  • 2009. Tumor virology - history, status and future challenges. 382-399.
  • 2007. Global gene expression in classification, pathogenetic understanding and identification of therapeutic targets in Acute Myeloid Leukemia. 344-354.
  • 2007. Early gene expression of acute myeloid leukemia in response to chemotherapy. 741-751.
Faglig kapittel
  • 2019. Hepatittvirus. 340-344. I:
    • 2019. Medisinsk mikrobiologi. Gyldendal Akademisk.
  • 2009. Molecular microbial diagnostics. 336-364. I:
    • 2009. Molecular Biology and Biotechnology 5th Ed. Springer.

Se fullstendig oversikt over publikasjoner i CRIStin.

Forskergrupper